Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tivic Health Systems (TIVC) Research & Development (2021 - 2025)

Tivic Health Systems has reported Research & Development over the past 5 years, most recently at $858000.0 for Q3 2025.

  • Quarterly results put Research & Development at $858000.0 for Q3 2025, up 103.32% from a year ago — trailing twelve months through Sep 2025 was $2.2 million (up 62.76% YoY), and the annual figure for FY2024 was $1.3 million, down 20.66%.
  • Research & Development for Q3 2025 was $858000.0 at Tivic Health Systems, up from $655000.0 in the prior quarter.
  • Over the last five years, Research & Development for TIVC hit a ceiling of $858000.0 in Q3 2025 and a floor of $175000.0 in Q3 2021.
  • Median Research & Development over the past 5 years was $360000.0 (2023), compared with a mean of $390842.1.
  • Biggest five-year swings in Research & Development: surged 158.85% in 2022 and later crashed 47.76% in 2024.
  • Tivic Health Systems' Research & Development stood at $313000.0 in 2021, then soared by 38.98% to $435000.0 in 2022, then fell by 17.24% to $360000.0 in 2023, then dropped by 7.5% to $333000.0 in 2024, then skyrocketed by 157.66% to $858000.0 in 2025.
  • The last three reported values for Research & Development were $858000.0 (Q3 2025), $655000.0 (Q2 2025), and $335000.0 (Q1 2025) per Business Quant data.